Valuation: Asymchem Laboratories (Tianjin) Co., Ltd.

Market Cap 5.23TCr 769.06Cr 672.28Cr 620.47Cr 573.05Cr 1.09TCr 73TCr 1.11TCr 7.44TCr 2.89TCr 36TCr 2.89TCr 2.82TCr 1,25000Cr P/E 2026 *
38.4x
P/E 2027 * 31.8x
Enterprise Value 4.72TCr 694.34Cr 606.96Cr 560.18Cr 517.37Cr 982.23Cr 66TCr 1TCr 6.72TCr 2.61TCr 33TCr 2.61TCr 2.55TCr 1,12900Cr EV / Sales 2026 *
5.86x
EV / Sales 2027 * 5.09x
Free-Float
61.14%
Yield 2026 *
0.99%
Yield 2027 * 1.19%
Manager TitleAgeSince
Chief Executive Officer 70 07/10/1998
Chief Executive Officer 49 19/01/2022
President - -
Director TitleAgeSince
Director/Board Member 49 18/07/2011
Chairman 70 07/10/1998
Director/Board Member 65 18/07/2011
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 787.22Cr
-1.60%+1.37%+57.31%+168.94% 1,10200Cr
-1.44%+3.71%+69.64%+65.40% 64TCr
-0.75%+0.44%+34.70%+86.52% 45TCr
-1.35%+0.63%+30.26%+26.28% 34TCr
-0.86%+0.99%+39.36%+40.85% 30TCr
-0.71%-0.54%+28.98%+48.27% 29TCr
-1.31%+2.72%-26.76%-39.82% 22TCr
-0.03%+1.62%+25.62%+68.30% 20TCr
-0.40%+7.50%+21.51%+82.50% 17TCr
Average -0.63%+2.47%+31.18%+60.81% 41.18TCr
Weighted average by Cap. -0.38%+2.14%+42.25%+86.55%

Financials

2026 *2027 *
Net sales 805.08Cr 118.45Cr 103.54Cr 96Cr 88Cr 167.56Cr 11TCr 170.92Cr 1.15TCr 445.86Cr 5.55TCr 444.77Cr 435.04Cr 19TCr 955.7Cr 140.61Cr 122.91Cr 113.44Cr 104.77Cr 198.91Cr 13TCr 202.9Cr 1.36TCr 529.27Cr 6.59TCr 527.98Cr 516.43Cr 23TCr
Net income 140.64Cr 21Cr 18Cr 17Cr 15Cr 29Cr 1.98TCr 30Cr 200.14Cr 78Cr 969.87Cr 78Cr 76Cr 3.36TCr 171.51Cr 25Cr 22Cr 20Cr 19Cr 36Cr 2.41TCr 36Cr 244.07Cr 95Cr 1.18TCr 95Cr 93Cr 4.1TCr
Net Debt -507.91Cr -75Cr -65Cr -60Cr -56Cr -105.71Cr -7.14TCr -107.83Cr -722.81Cr -281.28Cr -3.5TCr -280.6Cr -274.46Cr -12TCr -440.53Cr -65Cr -57Cr -52Cr -48Cr -92Cr -6.19TCr -94Cr -626.92Cr -243.97Cr -3.04TCr -243.37Cr -238.05Cr -11TCr
Logo Asymchem Laboratories (Tianjin) Co., Ltd.
Asymchem Laboratories Tianjin Co Ltd is a China-based company mainly engaged in providing one-stop comprehensive services for pharmaceutical outsourcing. The Company's business includes customized research and development and production of small molecule drugs (CDMO), chemical macromolecule CDMO, clinical research services, formulation CDMO, biological macromolecule CDMO, technology output and synthetic biology. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company mainly conducts its business in domestic and foreign markets.
Employees
10,617
Trader
Investor
Global
Quality
ESG MSCI
-